18.99
0.84 (4.63%)
| Penutupan Terdahulu | 18.15 |
| Buka | 18.15 |
| Jumlah Dagangan | 940,279 |
| Purata Dagangan (3B) | 532,098 |
| Modal Pasaran | 842,088,768 |
| Harga / Pendapatan (P/E Ke hadapan) | 40.98 |
| Harga / Jualan (P/S) | 2.55 |
| Harga / Buku (P/B) | 4.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | -3.68% |
| Margin Operasi (TTM) | -3.42% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 17.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 67.39% |
| Nisbah Semasa (MRQ) | 4.28 |
| Aliran Tunai Operasi (OCF TTM) | 3.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.84 M |
| Pulangan Atas Aset (ROA TTM) | -0.13% |
| Pulangan Atas Ekuiti (ROE TTM) | -7.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Menurun | Bercampur |
| Medical Devices (Global) | Menurun | Bercampur | |
| Stok | AxoGen, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.87% |
| % Dimiliki oleh Institusi | 86.30% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (Lake Street, 57.98%) | Beli |
| Median | 25.00 (31.65%) | |
| Rendah | 24.00 (Canaccord Genuity, 26.38%) | Beli |
| 24.00 (Cantor Fitzgerald, 26.38%) | Beli | |
| Purata | 26.00 (36.91%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 16.40 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 13 May 2025 | 24.00 (26.38%) | Beli | 10.88 |
| Lake Street | 17 Mar 2025 | 30.00 (57.98%) | Beli | 18.28 |
| Cantor Fitzgerald | 05 Mar 2025 | 24.00 (26.38%) | Beli | 18.21 |
| Citizens Capital Markets | 05 Mar 2025 | 26.00 (36.91%) | Beli | 18.21 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 May 2025 | Pengumuman | Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference |
| 08 May 2025 | Pengumuman | Axogen, Inc. Reports 2025 First Quarter Financial Results |
| 08 May 2025 | Pengumuman | Axogen Announces Chief Financial Officer Transition |
| 24 Apr 2025 | Pengumuman | Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 |
| 24 Mar 2025 | Pengumuman | Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |